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Molecular cloning of a cell-surface glycoprotein that can potentially
discriminate mesothelium from epithelium: its identification as vascular
cell adhesion molecule 1
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S_n..mary It has long been a practical problem for surgical pathologists to distinguish mesothelium from
epithelium in order to make a positive diagnosis of mesothelioma. In this study, we developed a new
monoclonal antibody, designated MS-2761 (IgGI, k), against cultured non-neoplastic mesothelial cells.
Immunohistochemistry and slot-blot analysis revealed that this monoclonal antibody reacted with 100%
(12 12) of benign and malignant mesothelioma tissues and a mesothelioma cell line, but not with 99% (77 78)
of epithelial tumour tissues and 97% (33 34) of epithelial tumour cell lines. A gene encoding the cell-surface
antigen defined by this monoclonal antibody was isolated from a mesothelial cell cDNA library constructed
with a mammalian cell expression vector through transfection of Cos-7 cells and immunoselection by panning.
DNA sequencing and a database search revealed that the gene was identical to vascular cell adhesion molecule
1 (VCAM1, also referred to as INCAM 110). The prominent VCAM1 transcript in mesothelium was 3.2 kb in
size with seven Ig-like domains. in addition to a minor transcript with six Ig-like domains. This monoclonal
antibody potentially discriminates mesothelium from epithelium and may become a tool for differential
diagnosis of mesothelioma.
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The mesothelium is a flat epithelial-like cell lining covering
the surface of the pleural. penrcardial and peritoneal cavities
and the serous surface of various organs located in these
cavities. It has long been a practical problem for surgical
pathologists to distinguish the mesothelium from the
epithelium and make a positive diagnosis of mesothelioma, a
tumour of mesothelial cell origin, because of its histological
similarity to epithelial tumours and the variation in its his-
tology. Mesothelioma is not a common malignancy in
humans, but epidemiological studies have established a rela-
tionship between malignant mesothelioma and exposure to
asbestos fibres (Craighead and Mossman, 1982). Definitive
diagnosis of mesothelioma is necessary not only for making
decisions regarding therapy and prognosis, but also for
prevention of this life-threatening disease.
Although long and slender cytoplasmic processes are
known to be one of the characteristic ultrastructural features
of mesothelium and mesothelioma (Warhol et al., 1982),
electron microscopy is a rather troublesome procedure, and
impractical for routine pathological diagnosis. In order to
discriminate between mesothelium and epithelium, numerous
immunohistochemical and immunocytochemical studies have
been performed using panels of antibodies against epithelial
cell markers with various degrees of specificity and sen-
sitivity, including carcinoembryonic antigen (CEA), epithelial
antigen (EA), Leu-MI, Tn antigen and the B72.3 antigen, as
reviewed previously (Sheibani et al., 1992). However, these
epithelial cell-surface markers cannot be used for positive
identification of mesothelium and mesothelioma.
In contrast, relatively few immunohistochemical studies
have been done using newly established polyclonal (Donna et
al., 1988) or monoclonal (Hsu S-H et al., 1988; Stahel et al.,
1988; O'Hara et al., 1990; Chang et al., 1992) antibodies
directed against mesothelium. Those include ME-1 (Stahel et
al., 1988; O'Hara et al., 1990) and K-1 (Chang et al., 1992).
Again, however, there is some limitation in the use of these
monoclonal antibodies. For example, ME-1 reacts with
poorly differentiated adenocarcinoma and K-1 reacts with
ovarian carcinoma and squamous cell carcinoma.
In this study, we developed a new monoclonal antibody,
designated MS-2761, against cultured non-neoplastic
mesothelial cells. We found that the antigen was expressed in
all non-neoplastic mesothelium and mesothelioma cells
examined, but was not expressed in epithelium and most
epithelial tumour cells in vivo and in vitro. Because of its
possible value for differential diagnosis of mesothelioma and
mesothelial cells and its unique tissue distribution, we
decided to carry out molecular cloning of the gene encoding
the cell-surface antigen defined by this monoclonal antibody
using a mammalian cell expression vector and immunoselec-
tion (Seed and Aruffo, 1987).
Materials and methods
Cell culture and cell tines
Mesothelial cells from six patients were separated from
peritoneal omentum, which had been removed during resec-
tion of stomach cancer, by brief trypsinisation as described
previously (Kern et al., 1983; Takahashi et al., 1989).
Routine pathological examination revealed no evidence of
peritoneal spread of cancer in the omentum used. Cells were
cultured in RPMI-1640 medium (IBL, Fujioka, Japan) supp-
lemented with 20% heat-inactivated fetal calf serum (FCS)
(Gibco BRL, Gaithersburg, MD, USA). Details of the
separation and tissue culture of non-neoplastic mesothelial
cells will be described elsewhere by the authors. The malig-
nant mesothelioma cell line, NCC-MS-1, was established
from the pleural effusion of a patient with malignant
mesothelioma. The establishment and characterisation of
NCC-MS-1 will be described elsewhere.
Forty-two established cell lines of various histology and
origin used in this study included the following:
* Eleven lung cancers
four adenocarcinomas: NCC-Lu9O (Hirano et al., 1989),
PC3, PC7 and PC9;
three squamous cell carcinomas: PCI, PC1O and PC13;
two large-cell carcinomas: NCC-Lu65 and NCC-Lu99
(Yamada et al., 1985);
two small-cell carcinomas: NCI-H69 and NCI-N231
(Carney et al., 1985).
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October 1994* Two breast cancers: R27 and MCF7 (Soule et al., 1973).
* Six stomach cancers: KATO-III, MKN1, MKN7,
MKN28, MKN45 and MKN74 (generous gifts from Dr
K Suzuki, Niigata University, Niigata, Japan);
* Six ovarian cancers: RMG1, RMG2, RMVG-S, RTSG
(generous gifts from Dr S Nozawa, Keio University,
Tokyo, Japan), MCAS and TYKnu [obtained from the
Japanese Cancer Research Resources Bank, (JRCB),
Tokyo, Japan].
* Three hepatomas: NCC-Li7, NCC-Li2l (established in
our laboratory) and Hep-G2 (Aden et al., 1979).
* Two pancreatic cancers: PAl (established in our labor-
atory) and PaCA-2 (JCRB).
* Two colon cancers: SW837 (JCRB) and HCT15 (obtained
from the American Type Cultu Collection, Rockville,
MD, USA).
One urinary bladder cancer: T24 (Bubenik et al., 1973).
* One vulvar epidermoid cancer: A431 (Giard et al., 1973).
* Three haematopoietic tumours: K234, K562 and HL60
(JCRB).
* Two fibroblast lines: TIG3 (JCRB) and VA4 (Hayflick
and Moorhead, 1961).
* Two non-neoplastic endothelial cell lnes: HUVEC (estab-
lished in our laboratory) and ECV 304 (Takahashi et al.,
1990).
PCI, PC3, PC7, PC9, PC1O, PC13 were generous gifts
from Dr Y Hayata, Tokyo Medical College, Tokyo, Japan.
A monkey kidney epithelial cell line expressing SV40 large T
antigen, Cos-7 (Gluzman, 1981) was obtained from Riken
Cell Bank, Tsukuba, Japan. The cell lines were cultured m
RPMI-1640 suplemented with 10% FCS.
Production ofmonoclonal antibody
One million cultured non-neoplastic mesothelial cells were
inoculated into Balb/c mice intraperitoneally three times
every 2 weeks. Spleen cells were separated and fused with
P3-X63-Ag8-Ul mycloma cells to obtain hybridomas as des-
cribed previously (Yamada et al., 1987). The hybridomas
were cultured with RPMI-1640 supplemented with 15% FCS
and 10% Hybridoma Cloning Factor (Igen, Rockvillk, MD,
USA).
The supernatant of the hybridomas was initially screened
for reactivity with cultured non-neoplastic mesothelial cells
and NCC-Lu99 lung cancer cells. Hybridomas reacting with
only the former were selce and subjected to a second
screening of reactivity with acetone-fixed paraffin-embedded
(AMeX; Sato et al., 1986)) human mesothelioma and lung
adenocarcnoma tissues as described below. A hybridoma
reactng immunohistochemically with only mesothelioma was
cloned by limiting dilution.
Immunoperoxidase staining ofcelLs and imhohistochemistry
For immunoperoxidase staining, monolayer cultured cells
were fixed with 95% methanol. Floating cells were cent-
rifuged to obtain cell smears prior to fixation.
For immunohistochemistry, 12 cases of mesothelioma (five
benign fibrous mesotheliomas and seven malignant
mesotheliomas, which included one epithelioid and one
fibrous monophasic mesotheliomas and five biphasic
mesotheliomas), 33 lung cancers, two metastatic lung
tumours, ten stomach cancers, 23 breast cancers and ten
ovarian tumours were selected from the surgical pathology
files of the National Cancer Center Hospital. The histological
subtyping of these tumours is described in Table II. Non-
neoplastic human tissues were collecte by autopsy from six
individuals. Tssues were cut from orans including the brain,
spinal cord, thyroid, tongue, breast, bronchus, lung, stomach,
small and large intestine, spleen, liver, pancreas, kidney,
adrenal gland, prostate, ovary and testis. No history of
defined asbestos exposure was obtaied in any case of
mesothelioma. Non-neoplastic and neoplastic tisues had
been fixed with cold acetone and embedded in paraffin
(AMeX method) as described previously (Sato et al., 1986).
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The immunoperoxidase staining procedures were per-
formed as described previously (Sato et al., 1986).
Slot-blot analyses
Cells were lysed in lysis buffer (10 mM HEPES pH 7.4,
150 mM sodium chloride, 2 mM calcium chloride, 1%
Nonidet P-40, 1% Triton X-100, 0.1% sodium azide, 1 mM
phenyl ethyl sulphonyl fluoride, 8 zgml-' aprotinin). Five or
ten micrograms of protein of cell lysates was blotted onto
0.45pm nitrocelluose membranes (Schleicher & Schuell,
Dassel, Germany) using a filtration manifold (Minifold II,
Schleicher & Schuell). Hybridoma supernatant was applied to
the membrane at 4-C overnight. In negative controls, normal
mouse IgG (Caltag Lab, South San Francisco, CA, USA)
was used in place of hybridoma supernatant. Membranes
were successively incubated with horadish peroxidase-
conjugated goat anti-mouse IgG (IBL), and the blots were
detcted with ECL Western blotting detection reagents
(Amenrsham, UK), as intructed by the supphers.
Immunoprecipitation
Non-neoplastic mesothelial cells were metabolically labeled
with 200#&Ci of [3Sjmethionine (Amersham) for 3 h at 37C.
A cell lysate was prepred as described above and precleaned
with normal mouse IgG bound to Affigel protein A (BioRad)
overnight at 4-C. The precleaned cell lysate was
immunoprecipitated with monoclonal antibody MS-2761 or
normal mouse IgG bound to Affigel protein A overnight at
4-C. After washing, samples were heat-denatured at OO-C
for Omin in buffer containing 0.5% sodium dodecyl sul-
phate (SDS) and 1% P-mercaptoethanol. The samples were
incubated overnight at 37C in the presence or absence of
100 U m-' N-glycosidas F (PNGase F, New England
BioLabs, Beverly, MA, USA) and analysed by 7.5% SDS
polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli,
1970).
mRNA isolation and cDNA library construction
mRNA was isolated using a FastTrack mRNA isolation kit
from Invitrogen (San Diego, CA, USA) as instructed by the
supplier. cDNA was synthesise by priming with NotI oligo-
dT primer using a SuperScript Plasmid system from Gibco
BRL and ligated with BstXI adaptor. After digestion with
NotI restriction enzyme, cDNA was ligated into a BstXI-and
NotI-digested pcDNA I/Amp (Invitrogen) mammalian cell
expression plasmid vector, a derivative ofpCDM8 (Seed and
Aruffo, 1987), to construct a directional cDNA library.
Escherichia coli WM 1100 cells were transformed by elect-
roporation.
Imnunoselection bypaning
A pool ofpcDNA I/Amp library reprLesting approximately
2.5 x 10' cDNA clones was introduced into Cos-7 cells by
ekctroporation and screened by the panning method (Seed
and Aruffo, 1987) with monoclonal antibody MS-2761. Two
days after tansfection, the cells were incubated overnight
with MS-2761 hybridoma supernatant at 4C, and distributed
into 60 mm panning dishes (Falcon, Lincln Park, NJ, USA)
that had been coated with goat anti-mouse IgG (Cappel,
West Chester, PA, USA). Episomal plasmid DNA was col-
lcted from cells adherent to the dishes (Hirt, 1967), intro-
duced into E. coli WM 1100 by electroporation and amplified
for a second round of panning. Thse paning cedures
were repeated three times. Resulting individual plasmid
clones were transfected into Cos-7 and cells were stain with
MS-2761 as described above. Simultaneous transfection of
Cos-7 with the pcDNA I/Amp vector alone served as a
negative control.Expression o VAU1 in mes-uisa m
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DNA sequencing
The cDNA inserts of clones were sequenced by the dideoxy
chain-termination method (Sanger et al., 1977) using a
Sequenase 7-deaza-dGTP kit from United States
Biochemicals (Cleveland, OH, USA).
Northern blot analysis
Northern blot analysis was performed essentially as described
previously (Sambrook et al., 1989). Briefly, 1 ;Lg of mRNA
was fractionated by 1.2% agarose/formaldehyde gel elect-
rophoresis and transblotted to nylon membrane (Hybond N,
Amersham) via capillary blotting. A 1.5 kb 5' EcoRI frag-
ment of the pMS2761-28 insert (described below) was ran-
dom primed and labelled with [32PdC(TP (Amersham) using a
DNA labelling kit from Pharmacia P-L Biochemicals (Mil-
waukee, WI, USA). The blot was hybridised with the labelled
probe overnight at 42'C in a solution of 10% dextran sul-
phate, 50% formamide, 6 x SSPE, 5 x Denhardt's reagent;
0.5% SDS and l00Lgml-' denatured sheared salmon testis
DNA. The membrane was washed and exposed to X-ray film
with an intensifying screen.
The quality and quantity of electrophoresed mRNAs were
determined by rehybridisation of the same blot with a human
glyceraldehyde 3-phosphate dehydrogenase (G3PDH) cDNA
probe.
In immunoperoxidase staining, almost 100% of cells were
stained strongly with MS-2761 in the primary culture of
non-neoplastic mesothelial cells, but only 10-20% of the
cells were stained in mesothelioma cell line NCC-MS-1 and
hepatoma cell line NCC-Li2I.
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Reverse transcription andpolymerase chain reaction
(RT-PCR)
First-strand cDNA was synthesised by random priming from
0.5 1Lg of mRNA at 42'C for 1 h in the presence of 5 U ml
AMV reverse transcriptase (Invitrogen). One-tenth of the
first-strand reaction was amplified by PCR. PCR primers
were as described by Hession et al. (1991): oligomer
370-y was 5'-GGAACCTITGCAGCTTACAGTGACAGAG-
CTCCC-3', and oligomer VC16 was 5'-CAAGTCTACAT-
ATCACCCAAG-3'. Samples were amplified in the presence
of 200jsM dNTP, 1.OM of each primer and 0.025 U ml'
AmpliTaq DNA polymerase using a thermal cycler (Perkin
Elmer-Cetus, Emeryville, CA, USA) and 30 cycles of 94°C
(30 s), 55°C (30 s) and 72°C (60 s). Polymerase chain reaction
products were analysed by electrophoresis on a 2% agarose
gel and ethidium bromide staining. The quality and quantity
of the template cDNA were determined by simultaneous
amplification of a 721 bp fragment of A-actin cDNA.
10-
11 -
Flgwe 1 Slot-blot analysis. A representative result of slot-blot
analysis is shown. Five micrograms of protein of lysate of non-
neoplastic mesothelial cells (Al) and 10ILg of protein of cell
lysate of mesothelioma cell line NCC-MS-1 (A2), Cos-7 (A3),
K234 (A4), K562 (A5), HL60 (A6), PC3 (A7), PC7 (A8), PC9
(A9), PCI (AIO), PCIO (All), PC13 (BI), NCC-Lu99 (B2),
NCC-Lu65 (B3), RMG1 (B4), RMG2 (B5), MCAS (B6),
HUVEC (B7), TIG3 (B8), A431 (B9), PAl (BO0), PaCA-2 (BI 1),
HCT15 (Cl) and NCC-Li7 (C2) was blotted onto a nitrocellulose
membrane using a filtration manifold. In slots C3-ClI, no sam-
ples were loaded. Blots were detected by monoclonal antibody
MS-2761 and an ECL Western blotting detection system
(BioRad). Non-neoplastic mesothelial cells (Al), non-neoplastic
endothelial cells (HUVEC) (B7) and mesothelioma cell line NCC-
MS-1 (A2) are reactive with monoclonal antibody MS-2761, but
other cell lines are not No signal is evident in the negative
control (data not shown).
Results
Production ofmonoclonal antibody MS-2761 and its reactivity
with cultured cells (Figure I and Table 1)
A murine monoclonal antibody designated MS-2761 (IgGl,
k), was generated by immunising mice with cultured non-
neoplastic mesothelial cells. Immunoperoxidase staining and
slot-blot analysis (Figure 1 and Table I) revealed that this
monoclonal antibody reacted with all (6/6) of the primary
cultures of non-neoplastic mesothelial cells separated from
the omentum and with a mesothelioma cell line (1/1). Except
for one hepatoma cell line, NCC-Li2l, MS-2761 did not
react with tumour cell lines of epithelial origin, which
included 11 lung cancers, two breast cancers, six stomach
cancers, two hepatomas, six ovarian cancers, two pancreatic
cancers, two colon cancers, one urinary bladder cancer and
one vulvar epidermoid cancer (Table I). MS-2761 showed
reactivity with one (HUVEC) of two cell lines of endothelial
origin (Figure 1). Two fibroblast and three haematopoietic
tumour cell lines examined did not express the antigen
defined by MS-2761. The results of immunoperoxidase stain-
ing and slot-blot analysis completely matched each other
with regard to the reactivity of MS-2761.
Table I Reactivity of monoclonal antibody MS-2761 with cultured
non-neoplastic and neoplastic cells in vitro
Positive
Tissue of origin (examined) Percentage
Non-neoplastic
Mesothelium 6/6 100
Endothelium 1/2 50
Fibroblast 0/2 0
Neoplastic
Mesothelioma 1/1 100
Lung cancer 0/11 0
Ovary cancer 0/6 0
Stomach cancer 0/6 0
Pancreatic cancer 0/2 0
Colon cancer 0/2 0
Breast cancer 0/2 0
Bladder cancer 0/1 0
Liver cancer 1/3 33
Vulva cancer 0/1 0
Hematopoietic 0/3 0
Summary of immunoperoxidase staining and slot-blot analysis.
Experiments were repeated at least twice to confirm the consistency
of the results. The results of immunoperoxidase staining and
slot-blot analysis of these cultured cells coincided with each other.Immwwhistochemical reactivity ofMS-2761 (Figures 2 and3
and Table II)
In 12 cases ofpleural mesothelioma, histopathologically diag-
nosed at the National Cancer Center Hospital, Tokyo,
acetone-fixed and paraffin-embedded tissues (AMeX; Sato et
al., 1986) were available and and selected for this study.
Among the 12 cases, five were classified as benign fibrous
mesothelioma of the pleura. Histologially, benign fibrous
mesothelioma is characterised by abundant dense collagenous
materials. Immunohistochemically, MS-2761 reacted with the
surfaces of mesothelioma cells, forming a network in the
dense fibrous stroma (Figure 2a). Among the seven cases of
malignant mesothelioma, two were classifie as monophasic
epithelioid or fibrous mesothelioma and five as biphasic
mesothelioma. In epithelioid mesothelioma or the epithelioid
component of biphasic mesothelioma, the MS-2761 antigen
was expressed on the inner surface of the gland-like spaces
formed by the tumour cells (Figure 2b) or in the cytoplasm
of the tumour cells (Figure 2c). When compared with
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epithelioid mesothelioma, the staining itensity of fibrous
mesothelioma or the sarcomatous component of biphasic
mesothelioma was relatively faint and the cytoplasm of the
tumour cells was stained (Figure 2d).
As shown in Table II, all the epithelial tumour cells except
for one small-cell lung cancer (77/78) were immunohis-
tochemically negative for the MS-2761 antigen. These
tumours included lung adenocarcinoma, breast cancer,
ovaran cancer and stomach cancer, all of which are known
to metastasise frequently or spread to the pleura or
peritoneum (Chernow and Sahn, 1977) and often create pro-
blems of differential diagnosis from mesothelioma. One
small-cell lung cancer positive for MS-2761 was from a
patient who was given extensive chemotherapy prior to sur-
gical resection of the tumour. This cancer showed intercel-
lular membranous staining with MS-2761 (Figure 2e). This
staining pattern was not observed in epithelioid
mesothelioma. In one case of lung adenocarcinoma, a small
number (<5%) of tumour cells at the edge (or the prolifera-
tion tip) showed membranous staining (Figure 2f).
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Figwe 2 Immunohistochemical detection ofMS-2761 antigen in human tumours. Immunoperoxiase staining (ABC method; Hsu
et al., 1981) was performed on AMeX tissue soctions (Sato et al., 1986). (a) Benign fibrous mesotheioma. Cell membrane of
tumour cells is stained with monoclonal antibody MS2761. (b) Malignant epitheioid mesotheioma- The inner surface of the
gland-ike spaces formed by tumour ells is stained. (c) Malignant epitheioid mesotheioma. Tumour cells show cytoplasmic
granular staining. (d) Malignant fibrous mesotheioma. Cytoplamic staining is detected in the tumour cells. (e) Small-celllbng
cancer. In one out of six smal-cell hmg cancers (16%) intercdlular membranous staing is observed, in contrast to the staining
pattern of mesotheioma. (f) Lung adenocarcioma. Intercellular staining is evient only in one cell nest at the edge (or
proliferation tip) of this tumour (arrow). Magntion: a and d x 90; b, c and f x 180; e x 360.
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Although tumour cells were not stained with MS-2761,
strong staining was observed in the fibrous stroma of most
epithelial tumours (Figure 3a).
In non-neoplastic issues obtained at autopsy, mesothelium
(Figure 3b), vascular endothelium (Figure 3c), epithelium of
Bowman's capsule (Figure 3d), Kupffer ceils of liver
sinusoids (Figure 3e), dendri fibres of lymph follicles and
adrenal cortex cells (Figure 3f) were stained with MS-2761.
When hybridoma supematant was replaced by normal mouse
IgG, no staining was observed in these issues (data not
shown).
Immunoprecipitation (Figure 4)
In order to detrmine the molecular weight and N-
glycosylation status of the antigen in mesothelium defined by
monoclonal antibody MS-2761, immunoprecpitation and
subsequent N-glyCodase treatMent were performed. 3S-
Labelled cell lysate of cultured non-neoplastic mesotheial
cells was immunoprecipitated by MS-2761 antibody and sub-
jected to SDS-PAGE and autoradiography. Under reducing
conditions, a major and rather broad band at 106-112 kDa
and a minor and sharp band at 97 kDa were detected (Figure
4, lane A). After N-glycosidase treatment, which cleaves
between the innermost N-acetylglicosamine (GlcNAc) and
asparagine residue of glycoprotein (Tarentino et al., 1990), a
single band at 80-82 kDa was detected (Figure 4, lane B).
This s d that the antigen molecule defined by MS-2761
has two different forms of N-glycosylation.
Molecular cloningofthe gene that encodes MS-2761
glycoprotein
The potential vahle for differential diagnosis ofmesothelioma
and its unique tissue distribution encouraged us to carry out
molecular cloning of the gene encoding the cell-surface
glycoprotein defined by this monoclonal antibody. Because
the antigenicity was labile to heat denaturation, SDS or a
high concentration of urea (data not shown), monoclonal
antibody MS-2761 was considered to recognise the confor-
Flgwe 3 Imuno b l decton ofMS-2761 antign in human tisses Imm oproxidase s (ABC method; Hsu et
at., 19981) was perfo on AMeX tissue sections (Sato et at., 1986). (a) Lung Exession of MS2761 antigen is
observed in the fibrous cancer stroma but not m any of the cancer celk. (b) V eral pieura of the hmg. M hehial cels coverig
the serous surface of the lung and subplra vascular endoteli cells are stained. (c) Lung. Vascular ial cells are stained,
but no staining is evidnt in alveolar cells (d) Kidney. Epitheum of Bowman's capsule is stained. (e) liver. The cytoplasm of
Kupffer cells in liver sinusoids is stained, but liver parenchymal cells are stained. (f) Adrenal cortex. Cell membane of adrenal
cortex cels is stained. Magnification: a and c x 90; b and d x 360; e and fx 180.Table I Immunohistochemical reactivity of monoclonal antibody
MS-2761 with human tumour tissues
Organ of origin Positivel
Histological subtype examined Percentage
Mesothelioma
Benign, fibrous 5/5 100
Malignant, epithelioid '11 100
Malignant, fibrous 1/1 100
Malignant, biphasic 5/5 100
Lung cancer
Adenocarcinoma Oa 18 0
Squamous cell carcinoma 015 0
Large-cell carcinoma 0/4 0
Small-cell carcinoma 1/6 16
Metastatic lung tumour
Colorectal carcinoma 0 2 0
Breast cancer
Invasive ductal carcinoma 0 22 0
Medullary carcinoma 0,1 0
Ovarian tumour
Mucinous cystadenoma 0 1 0
Serous papillary 0,4 0
adenocarcinoma
Mucinous cystic 0 2 0
adenocarcinoma
Clear cell adenocarcinoma 0 1 0
Malignant clear cell 0 1 0
adenofibroma
Immature teratoma 0,1 0
Stomach cancer
Adenocarcinoma 0 10 0
'In one case of lung adenocarcinoma, a small number (<5%) of
tumour cells at the edge (or the proliferation tip) showed membrane
staining (Figure 2f).
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mational structure of the antigen molecule. Therefore, we
decided to construct a cDNA library to express the antigen
in Cos-7 monkey kidney cells and select cDNA clones by
panning, as described by Seed and Aruffo (1987). After the
third panning, restriction digestion analysis revealed that
cDNA clones with insert sizes of 3.2 kb and 2.8 kb had
become prominent. Among 15 clones picked randomly, five
clones had identical inserts 3.2 kb in size and four had iden-
tical inserts of 2.8 kb. By transfecting into Cos-7 cells and
subsequent immunoperoxidase staining, two representative
clones, pMS2761-32 (3.2 kb) and pMS2761-28 (2.8 kb), were
found to contain the cDNA of the molecule possessing the
MS-2761 antigenic determinant. Cos-7 cells transfected with
the pCDNAl/Amp vector alone were not reactive with MS-
2761.
DNA sequencing and database search
As shown in Figure 5, DNA sequencing and restriction
mapping revealed that the two cDNA clones shared an iden-
tical 5' end sequence and an identical open reading frame but
different polyadenylation sites. A database search revealed
that the nucleotide sequence was identical to the cDNA of
vascular cell adhesion molecule 1 (VCAM1), which was
originally cloned from an expression library of cytokine-
activated endothelial cells (Osborn et al., 1989). Both
pMS2761-32 and pMS2761-28 had four additional
nucleotides (GCAT) at the 5' end of the registered VCAM1
cDNA sequence, but lacked seven nucleotides from the trans-
criptional start site determined by primer extension analysis
(Cybulsky et al., 1991b).
Northern blotting (Figure 6)
mRNA expression of non-neoplastic mesothelial cells from
two individuals, mesothelioma cell NCC-MS-1, ovarian
cancer cell line TYKnu, lung cancer cell line NCC-Lu99 and
liver cancer cell line NCC-Li2l was electrophoresed and
hybridised with a radiolabelled 1.5 kb 5' fragment of the
pMS2761-28 insert (Figure 5). Non-neoplastic mesothelial
cells expressed a predominant 3.2 kb transcript (Figure 6,
lanes A and B). The VCAM1 expression ofmesothelioma cell
line NCC-MS-1 (lane C) and liver cancer cell line NCC-Li2I
(lane F) was much lower than that of non-neoplastic
mesothelial cells. TYKnu (lane D) and NCC-Lu99 (lane E)
did not express VCAM1 mRNA. In addition to a 3.2 kb
transcript, 7.5 and 5.0 kb mRNAs, not described before, were
detected in non-neoplastic mesothelial cells (Figure 6, lanes A
and B). These results were consistent with the reactivity of
these cells with monoclonal antibody MS-2761.
EcoRI
Flgwe 4 Immunoprecipitation of MS-2761 antigen and subse-
quent N-glycosidase treatment. 3S-Labelled cell lysate of non-
neoplastic mesothelial cells was immunoprecipitated by monoc-
lonal antibody MS-2761 (lanes A and B) or normal mouse IgG
(lanes C and D). Molcular weights (in kDa) were determined by
sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) under reducing conditions and autoradiography.
Without N-glycosidase treatment, a major broad band at
106-112kDa and a minor one at 97 kDa are detected (lane A).
After treatment of the immunoprecipitates with N-glycosidase, a
single band 80-82 kDa in size is evident (lane B). When monoc-
lonal antibody MS-2761 is replaced by normal mouse IgG, no
signal is detected (lanes C and D).
500 bp
pMS2761-32 (A),
pMS2761-28 (A)n
MIIMTTATGOKCATAGAAGATrGcTrT
cDNA prbe
Fugwe 5 Structure of human VCAMI cDNA, pMS2761-32 and
pMS2761-28. The schematic structure of two cDNA clones,
pM2761-32 and pMS2761-28, obtained in this study is presented,
in comparison with the registd VCAMI cDNA sequence (top).
pM2761-32 and pMS2761-28 have identical 5' side sequences but
different polyadenylation sites. The 3' end sequence preceding the
polyadenylation site of pMS2761-28 is shown. The consensus
polyadenylation signal AATAAA is underlined. A 1504 bp 5'
fragment of the pMS2761-28 insert (bottom) was used as a probe
for Northern blotting.F hw_ dVCAIU in_ e
v ~~~~~~~~~~~~~~~~~~T Yamnada etai
RT-PCR (Figure 7)
In endothelial cells, alternative splicng results in two
different mRNAs encoding VCAM1 with six or seven Ig-ke
domain (Cybulsky et al., 1991a; Hession et al., 1991). In
order to determine if the VCAM1 in non-vascular cells has
six or seven Ig-like domains, the region covering domains 3
and 4 was amplified (Figure 7), where alternative splicing
takes place in cytokine-activated endothelial cells. Non-
neoplastic mesothelial cells (lane A), mesothelioma cells
NCC-MS-1 (lane B) and NCC-Li21 bepatoma cells (lane E)
expressed both a predominent 631 bp PCR fragment and an
additional 355 bp PCR fragment, suggesting coexpression of
two types of transcripts with six and seven Ig-like domains.
The expression level was lower in NCC-MS-1 and NCC-Li21
than in non-neoplastic mesothelial cells. Expression of
VCAM1 mRNA in two other epithelial tumour cell lines,
TYKnu (lane C) and NCC-Lu99 (lane D), could not be
detected, even using such a sensitive method. These results of
RT-PCR are consistent with those of Northern blotting and
the reactivity of these cells with monoclonal antibody MS-
2761 described above.
Vascular cell adhesion molecule 1 [VCAM1, also referred to
as INCAMIIO (Rice and Bevilacqua, 1989)] is a member of
A B C D E F
7.5-
4.4-
2.4 -
1.4 -
VCAM1
G3PDH
Fuwe 6 Northern Uotting. Expression of VCAMI mRNA was
examined in non-neoplastic mesotheial cels from two individuals
(lanes A and B), mesothehoma cell he NCC-MS-1 (lane C), lung
cancrcell line NCC-Lu99 (lane D), ovarian cancer cell ine
TYKnu (lane E) and hepatoma cell line NCC-Li2l (lane F) by
Northern blotting Non-neoplastic mesothehal cells express a pro-
minent transcript 32 kb in size and two minor wanripts of 5.0
and 7.5 kb. NCC-MS-1 and NCC-Li2l also express the 32kb
transcript Two epithdial tumour cell lnes, NCC-Lu99 and
TYKnu, do not express VCAMI mRNA. The quality and quan-
tity of electrophoresed mRNAs were determined by rehybridisa-
tion of the same blot with a human glyceraklehyde-3-phosphate
dehydrogenase (G3PDH) cDNA probe (bottom).
Fugwe 7 RT-PCR for the detection of seven and six Ig-lke
domain forms of VCAM1 mRNA. Furst-strand cDNA of non-
neoplastic mesothehal cells (lanes B and G), mesotheioma cell
ine NCC-MS-1 (lanes C and H), ling cancer cell heNCC-Lu99
(lanes D and I), ovaran cancer cell lne TYKnu (lanes E and J)
and hepatoma cel ine NCC-Li2l (lanes F and L) was amplified
by PCR and analsed by agrose gel eectrophoresis and
ethidium bromide staining. VCAMI cDNA fragments of 631 bp
(sven Ig-like domains) and 335 bp (six Ig-like domains) were
amplified from the first-strand cDNA of non-neoplastic
mesotheli cells,NCC-MS-1 and NCC-Li2l but not from NCC-
Lu99 or TYKnu (lanes B through F). Lanes G-K show
amplfation of a 721 bp fragment of A-actin cDNA in these
ceII& Lanes A and L, mokcular weight marker (tOObp ladder,
Pharmacia).
the immunoglobuin (Ig) superfamily. VCAM1 cDNA was
originally separated from cytokie-activated endothelial cells
by Osborn et al. (1989). VCAM1 expression on resting
endothelial cells is minimal, but it can be induced by various
stimuli, including interieulin 1p (IL-10) and tumour necrosis
factor alpha (TNF-z) (Osborn et al., 1989). Through its
interaction with integrin aJ1 (Elices et al., 1990), VCAM1
acts as an adhesion molecule of endothelial cells to lym-
phocytes, monocytes, eosinophils and basophils, and is
thought to initiate the extravasation of these inflammatory
cells (Briscoe et al., 1992). The expression of VCAM1 in
inflammatory sites suggests its involvement in the
pathogenesis of inflammatory diseases (Rice et al., 1991).
Non-vascular cells expressing VCAM1 are reported to in-
clude follicular dendritic cells of lymph nodes, bone marrow
stroma cells and synovial cells (Freedman et al., 1990; Rice et
al., 1991; Simmons et al., 1992). Taking into consideration
the morphological and functional similarity between
endothelium and mesothelium, it is not surprising that
endothelium and mesothelium share such a cell-surface
molecule. The in vivo expression of VCAM1 in mesothelium
was described by Rice et al. (1991), but it has not been
examined in further detail, except for a few sporadic in vitro
studies (Jonjic et al., 1992; Cannistra et al., 1993). In the
present search for a new marker for discriminating
mesothelium from epithelium, we produced a monoclonal
antibody and identified VCAM1 as its antigen molecule by
expression cDNA cloning. We also demonstrated the selec-
tive reactivity of monoclonal antibody MS-2761 with non-
neoplastic mesothelium and mesothelioma both in vitro and
in vivo. Non-neoplastic mesothelial cells obtained from the
peritoneal omentum of six individuals uniformly expressed
MS-2761 antigen. All the cases of benign and malignant or
fibrous and epithelial mesothelioma examined in this study
reacted with this monoclonal antibody, but 77 out of 78
epithelial tumour tissues and 33 out of 34 epithelial tumour
cell lines were not reactive. Furthermore, the specific expres-
sion of VCAM1 glycoprotein in non-neopastic mesothelium
and mesothelioma was confirmed at the RNA level by
Northern blotting and RT-PCR. The high specificity of
MS-2761 for mesothelium suggests the potential usefulness of
this anti-VCAMI antibody for differential diagnosis of
mesothelioma.
Cultured non-neoplastic mesothelial cells constitutively
express VCAM1 even without cytokine stimuli. The
physiological role ofthe VCAM1 molecule on the cell surface
of the mesothelium has not yet been explored and remains to
be investigated.
In Northern blotting, a prominent 3.2 kb transcript of
VCAM1 was detected in non-neoplastic mesothelial cells. In
addition, two minor transcripts, 5.0 and 7.5 kb in size, were
also detected. These longer transcripts have not been de-
scribed in the literature and are now under investigation.
RT-PCR revealed that non-neoplastic mesothelial cells
expressed VCAM1 with both of six and seven Ig-like
domains, imilar to cytokine-activated endothelial cells
(Cybulsky et al., 1991a; Hession et al., 1991). In this study,
two near-full legth cDNAs of VCAM1 were separated by
expression cDNA cloning. Tmese two cDNA clones shared
identical 5' end sequencs but had different polyadenylation
sites. It is likely that the shorter cDNA done was the result
ofDNA recombination during the cloning procedures includ-
ing repeated transformation into E. coli and DNA transfec-
tion into Cos-7 monkey cells. However, the shorter cDNA
clone had a sequence identical to the longer one and a
polyadenylation site proceded by the consensus poly(A) sig-
nal sequence, AATAAA. This implies the presence of a
minor differently polyadenylated population of VCAM1
mRNA which has not been detected before.
The expression level of VCAM1 in mesothelioma cell line
NCC-MS-1 was much lower than its its non-neoplastic
counterparts. In fact, cytogenetic analysis has revealed that
the most frequent change seen in malignant mesothelioma is
deletion of chromosome lp (Taguchi et al., 1993), which
bears the VCAM1 gene (Cybulslky et al., 1991b). Deletion of
9-,' -::
,-(7Z -c
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a specific site on Ip may be responsible for partial down-
regulation of VCAM1 expression during the course of
oncogenesis. In our preliminary examination, however, no
apparent abnormality of the VCAM1 gene was detected in
NCC-MS-1 by Southern blotting (data not shown). Further
detailed studies on the mechanism of down-regulation of
VCAM1 gene expression appear to be necessary.
The tissue distribution of MS-2761 antigen was quite
similar to that of VCAM1 reported in the literature. How-
ever, through immunohistochemical analysis, we found that
the antigen defined by MS-2761 was strongly expressed in
cancer stroma. Histologically, cancer often shows massive
infiltration of inflammatory cells such as lymphocytes,
plasma cells and basophils. VCAM1 may act as an inducer of
these inflammatory cells into the cancer stroma. Cancer cells
and stroma interact with each other either directly or
through cytokine production. The expression of VCAM1 in
cancer stroma, described in this paper for the first time, may
play a role in the growth and invasion of cancer. We are
currently investigating the functional and molecular charac-
teristics of VCAMI in cancer stroma.
Unlike diffuse malignant mesothelioma, the histogenesis of
benign localised fibrous mesothelioma (or localised fibrous
tumour of the serous cavities) still remains controversial.
There is no conclusive evidence to indicate whether this
tumour is of mesothelial cell or of submesothelial connective
tissue origin. As MS2761 is reactive with cancer stromal
fibroblasts, it is likely that it reacts with some activated
mesenchymal cells. Thus, the possibility of benign fibrous
mesothelioma being of mesenchymal origin is not ruled out
solely because of its reactivity with MS-2761. Furthermore,
in fibrous mesothelioma or the sarcomatous component of
biphasic mesothelioma, the cytoplasmic staining of tumour
cells was indistinguishable from that of activated fibroblasts
in cancer stroma.
In conclusion, we have developed a new monoclonal
antibody for differential diagnosis of mesothelioma. Through
molecular cloning, we have identified the antigenic molecule
as VCAM1 in mesothelium. Detailed immunohistochemistry
revealed that this antigen is expressed in mesothelium and
mesotheliomas but not epithelium or most tumours of
epithelial origin. Currently, surgical pathologists use many
immunohistochemical markers in routine diagnosis. Many
immunoglobulin superfamily members such as CEA and
NCAM (Patel et al., 1989) are among those used most
commonly. This is probably due to the relatively restricted
tissue distribution of this family. Although a larger series of
tumours with different histological patterns needs to be
studied to confirm the specificity, this monoclonal antibody
seems to have a potential value for discrimination of
mesothelium and epithelium, and further studies of VCAMI
should provide insight into the functional properties of
mesothelium.
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